Lung Cancer Trials Ask AI to find trials
UnknownPhase 1 / Phase 2NCT04913337
Official study title

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Study summary

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNGM707 and NGM707 plus pembrolizumab (KEYTRUDA®)

Plus 6 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · Mesothelioma · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 2, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Unknown

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?27 U.S. locations

Locations may change over time.

Who runs it?NGM Biopharmaceuticals, Inc

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
NGM Biopharmaceuticals, Inc
Interventions being studied
Drug: NGM707; Drug: NGM707 plus pembrolizumab (KEYTRUDA®); Drug: NGM707 plus pembrolizumab (KEYTRUDA®); Drug: NGM707 plus pembrolizumab (KEYTRUDA®); Drug: NGM707 plus pembrolizumab (KEYTRUDA®); Drug: NGM707; Drug: NGM707; Drug: NGM707
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→Mesothelioma→
Disease setting
Metastatic or stage IV→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
  • Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit.
  • Adequate bone marrow, kidney and liver function.
  • Performance status of 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.
Reasons someone may not be able to joinExclusion criteria

Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • NGM Clinical Study SiteLos Angeles, California
  • NGM Clinical Study SiteNewport Beach, California
  • NGM Clinical Study SiteSanta Monica, California
  • NGM Clinical Study SiteSanta Rosa, California
  • NGM Clinical Study SiteLone Tree, Colorado
  • NGM Clinical Study SiteWashington D.C., District of Columbia
  • NGM Clinical Study SiteSarasota, Florida
  • NGM Clinical Study SiteBaltimore, Maryland
  • NGM Clinical Study SiteBoston, Massachusetts
  • NGM Clinical Study SiteGrand Rapids, Michigan
  • NGM Clinical Study SiteOmaha, Nebraska
  • NGM Clinical Study SiteAlbany, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 2, 2024. Always confirm current availability with the study team.

View original record ↗